Nanoparticle‐mediated siRNA delivery systems for cancer therapy DOI Creative Commons
Han Gao, Ruoyu Cheng, Hélder A. Santos

et al.

View, Journal Year: 2021, Volume and Issue: 2(3)

Published: Feb. 11, 2021

Abstract The small interfering RNA (siRNA)‐based therapeutics have raised great attention since the first interference (RNAi)‐derived drug, patisiran, was approved by US Food and Drug Administration, which represented a landmark in field of gene therapy. Given properties disease‐associated expression, RNAi machinery is regarded as an essential factor for preparing precise medicine. However, over past few years, siRNA drugs are undergoing period clinical translation, major hurdle limited efficient delivery strategies. Therefore, this mini‐review mainly focuses on describing state‐of‐the‐art nanoscale platforms delivering payloads, also addressing their applications cancer Finally, status under trials discussed, providing comprehensive understanding oligonucleotide‐mediated therapeutics.

Language: Английский

A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system DOI
Saman Yasamineh,

Pooneh Yasamineh,

Hesam Ghafouri Kalajahi

et al.

International Journal of Pharmaceutics, Journal Year: 2022, Volume and Issue: 624, P. 121878 - 121878

Published: May 28, 2022

Language: Английский

Citations

128
Application of molecular docking in elaborating molecular mechanisms and interactions of supramolecular cyclodextrin DOI
Tian‐Cheng Li, Ranran Guo,

Qida Zong

et al.

Carbohydrate Polymers, Journal Year: 2021, Volume and Issue: 276, P. 118644 - 118644

Published: Sept. 8, 2021

Language: Английский

Citations

124
Targeted Delivery Methods for Anticancer Drugs DOI Open Access
Valery V. Veselov,

Alexander E. Nosyrev,

László Jicsinszky

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(3), P. 622 - 622

Published: Jan. 26, 2022

Several drug-delivery systems have been reported on and often successfully applied in cancer therapy. Cell-targeted delivery can reduce the overall toxicity of cytotoxic drugs increase their effectiveness selectivity. Besides traditional liposomal micellar formulations, various nanocarrier recently become focus developmental interest. This review discusses preparation targeting techniques as well properties several liposome-, micelle-, solid-lipid nanoparticle-, dendrimer-, gold-, magnetic-nanoparticle-based systems. Approaches for targeted drug release under a range stimuli are also discussed.

Language: Английский

Citations

96
Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics DOI Creative Commons
Harshita Tiwari, Nilesh Rai, Swati Singh

et al.

Bioengineering, Journal Year: 2023, Volume and Issue: 10(7), P. 760 - 760

Published: June 25, 2023

Nano-oncology is a branch of biomedical research and engineering that focuses on using nanotechnology in cancer diagnosis treatment. Nanomaterials are extensively employed the field oncology because their minute size ultra-specificity. A wide range nanocarriers, such as dendrimers, micelles, PEGylated liposomes, polymeric nanoparticles used to facilitate efficient transport anti-cancer drugs at target tumor site. Real-time labeling monitoring cells quantum dots essential for determining level therapy needed The drug targeted site either by passive or active means. Passive targeting makes use microenvironment enhanced permeability retention effect, while involves ligand-coated nanoparticles. Nanotechnology being diagnose early stage detecting cancer-specific biomarkers imaging. implication employs photoinduced nanosensitizers, reverse multidrug resistance, enabling delivery CRISPR/Cas9 RNA molecules therapeutic applications. However, despite recent advancements nano-oncology, there need delve deeper into domain designing applying improved diagnostics.

Language: Английский

Citations

69
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination DOI Creative Commons
Ai‐Ming Yu,

Mei‐Juan Tu

Pharmacology & Therapeutics, Journal Year: 2021, Volume and Issue: 230, P. 107967 - 107967

Published: Aug. 14, 2021

The concepts of developing RNAs as new molecular entities for therapies have arisen again and since the discoveries antisense RNAs, direct RNA-protein interactions, functional noncoding RNA-directed gene editing. feasibility was demonstrated with development utilization synthetic RNA agents to selectively control target expression, modulate protein functions or alter genome manage diseases. Rather, are labile degradation cannot cross cell membrane barriers, making it hard develop medications. With viable technologies, such chemistry pharmaceutics, eight oligonucleotides (ASOs) (fomivirsen, mipomersen, eteplirsen, nusinersen, inotersen, golodirsen, viltolarsen casimersen), one aptamer (pegaptanib), three small interfering (siRNAs) (patisiran, givosiran lumasiran) been approved by United States Food Drug Administration (FDA) therapies, two mRNA vaccines (BNT162b2 mRNA-1273) under Emergency Use Authorization prevention COVID-19. Therefore, become a great addition molecules, proteins/antibodies, cell-based modalities improve public health. In this article, we first summarize general characteristics therapeutic agents, including chemistry, common delivery strategies, mechanisms actions, safety. By overviewing individual medications FDA some development, illustrate unique compositions pharmacological actions products. A era research will likely lead commercialization more medical use, expanding range targets increasing diversity modalities.

Language: Английский

Citations

65
Stimulus-responsive drug/gene delivery system based on polyethylenimine cyclodextrin nanoparticles for potential cancer therapy DOI
Hanieh Mousazadeh,

Esat Bonabi,

Nosratollah Zarghami

et al.

Carbohydrate Polymers, Journal Year: 2021, Volume and Issue: 276, P. 118747 - 118747

Published: Oct. 18, 2021

Language: Английский

Citations

60
Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets DOI Creative Commons

Ali Pourgholi,

Mehdi Dadashpour,

Akram Mousapour

et al.

Asian Pacific Journal of Cancer Prevention, Journal Year: 2021, Volume and Issue: 22(8), P. 2587 - 2596

Published: Aug. 1, 2021

Silibinin (SIL) is a natural polyphenolic flavonoid with multiple biological and anti-cancer features. However, the complex hydrophobic nature inadequate bioavailability of SIL hinder its efficiency at tumor sites. Investigating possibility an extensive strategy for better treatment breast cancer, we carried out comparative exploration inhibitory effect loaded PLGA-PEG nanoparticle (SIL-NPs) on expression proapoptotic target genes, which considered as influential molecular cancer. The main diameter SIL-NPs was 220 ± 6.37 150 23.14 nm via DLS FE-SEM respectively. Furthermore, zeta potential -5.48±0.13 -6.8±0.26 mV encapsulation drug release were determined by about 82.32 % analyzing calibration curve absorbance 570 nm. Cytotoxicity conducted MTT assay after 24, 48, 72 h exposure times, gene levels apoptotic p53 hTERT measured real-time PCR. Evaluation toxicity revealed that represents higher cytotoxic effects than pure in time dose-dependent manner. Moreover, results demonstrated could induce apoptosis cancer cells upregulation caspase-3, caspase-7, Bax, along Bcl-2, hTERT, survivin Cyclin D1 down regulation. Our indicated can be used stable carriers nano-dimensions promising pharmacological agent therapy.
.

Language: Английский

Citations

57
Dendrimers as nanoscale vectors: Unlocking the bars of cancer therapy DOI
Asmita Deka Dey, Ashkan Bigham, Yasaman Esmaeili

et al.

Seminars in Cancer Biology, Journal Year: 2022, Volume and Issue: 86, P. 396 - 419

Published: June 11, 2022

Language: Английский

Citations

57
The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action DOI

Nasim Hassani,

Davoud Jafari-Gharabaghlou, Mehdi Dadashpour

et al.

Applied Biochemistry and Biotechnology, Journal Year: 2022, Volume and Issue: 194(10), P. 4930 - 4945

Published: June 8, 2022

Language: Английский

Citations

51
Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation DOI Creative Commons

Elnaz Salmani Javan,

Fatemeh Lotfi, Davoud Jafari-Gharabaghlou

et al.

Asian Pacific Journal of Cancer Prevention, Journal Year: 2022, Volume and Issue: 23(2), P. 519 - 527

Published: Feb. 1, 2022

Chemotherapeutic combinational approaches would be more efficient in decreasing toxicity of drug, preventing tumor progression relation to either drug alone. Hence, the aim this study is constract magnetic PLGA/PEG nanoparticles (NPs) co-loaded with Metformin (Met) and Silibinin (Sil) investigate their cytotoxicity as well impact on mRNA expression levels leptin receptor genes A549 lung cancer cells.The synthesized NPs were characterized by FTIR, FE-SEM, VSM then, MTT assay was utilized assess compare various concentrations chemotheruptic molecules pure nanoformulated forms alone combination state after 48 h exposure time. Moreover, its studied quantitative real-time PCR. By co-encapsulation Met Sil into PLGA/PEG/ Fe3O4, cytotoxic efficiency compounds considerably augmented for all concentrations.Cytotoxicity displayed that had a synergistic concentration-dependent effect cells. qPCR data revealed reduced increasing drug-encapsulated NPs, especially Met/Sil-encapsulated Fe3O4 NPs.Present preliminary shows co-incorporating Met, Sil, might provide promising safe treatment strategy cancer.

Language: Английский

Citations

47